BioCentury
ARTICLE | Clinical News

Tecentriq meets endpoints in Phase III for extensive-stage SCLC

June 29, 2018 2:29 PM UTC

Roche (SIX:ROG; OTCQX:RHHBY) said first-line treatment with Tecentriq atezolizumab plus chemotherapy met the co-primary endpoints of improving overall survival (OS) and progression-free survival (PFS) compared with chemotherapy alone in the Phase III IMpower133 trial to treat extensive-stage small cell lung cancer (SCLC). The company plans submit the data to global health authorities, including FDA and EMA. The data will also be presented at a medical meeting.

The double-blind, international trial enrolled 403 chemotherapy-naïve patients to receive Tecentriq in combination with carboplatin and etoposide for four 21-day cycles followed by maintenance with Tecentriq, or placebo plus chemotherapy for four 21-day cycles followed by maintenance placebo...